Company Overview of Mirna Therapeutics, Inc.
Mirna Therapeutics, Inc., a biopharmaceutical company, is engaged in the development and commercialization of microRNA (miRNA) therapeutics. The company focuses on miRNA-directed oncology therapies. It offers MRX34, a series of clinical therapeutic candidates to mimic the activity of a human miRNA. Its product candidates target cancers, such as solid and blood-borne tumors with a focus on hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer, and pancreatic carcinoma. The company was founded in 2007 and is based in Austin, Texas. Mirna Therapeutics, Inc. operates as a subsidiary of Asuragen, Inc.
2150 Woodward Street
Austin, TX 78744
Founded in 2007
Key Executives for Mirna Therapeutics, Inc.
Chief Financial Officer and Secretary
Senior Vice President and General Counsel
Chief Medical Officer and Vice President of Oncology
Compensation as of Fiscal Year 2014.
Mirna Therapeutics, Inc. Key Developments
Mirna Therapeutics, Inc. Presents at BIO International Convention, Jun-23-2014
Jun 17 14
Mirna Therapeutics, Inc. Presents at BIO International Convention, Jun-23-2014 . Venue: San Diego Convention Center, San Diego, California, United States.
Mirna Therapeutics, Inc. Announces Interim Phase 1 Safety Data on Lead Product Candidate MRX34 at AACR Annual Meeting
Apr 8 14
Mirna Therapeutics, Inc. announced interim safety data from a multicenter, open-label Phase 1 clinical trial of MRX34 for the treatment of patients with unresectable primary liver cancer or solid cancers with liver involvement. The data show that MRX34 has a manageable safety profile with only one incident of a dose-limiting toxicity observed to date. The findings were presented by Dr. Muhammad Shaalan Beg, assistant professor of Internal Medicine and co-leader of the gastro-intestinal oncology group at University of Texas Southwestern Harold C. Simmons Cancer Center in Dallas, Texas, during an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, CA from April 5-9, 2014. The Phase 1 MRX34 study design consists of an initial dose-escalation phase of approximately 30 patients, followed by an expansion phase of approximately 18 additional patients after the recommended Phase 2 dose has been identified. MRX34 is administered intravenously (IV) twice a week for three weeks with one week off, during 28-day cycles, until disease progression or intolerance. Tumor response is measured by RECIST or modified RECIST (primary liver cancer) and evaluated by Computed Tomography/Magnetic Resonance Imaging (CT/MRI) every eight weeks. The expansion phase will include tumor biopsies and assessment of biological effect of MRX34. Data from the first 26 patients in the dose-escalation phase are included in the interim analysis. The primary objectives of the clinical trial are to establish the maximum tolerated dose and the recommended Phase 2 dose for future clinical trials. The secondary objectives are to assess the safety, tolerability and pharmacokinetic profile of MRX34 after IV dosing as well as to assess pharmacodynamics and clinical activity of MRX34.
Mirna Therapeutics Appoints Casi DeYoung as Chief Business Officer
Mar 19 14
Mirna Therapeutics announced Casi DeYoung has joined the company as chief business officer. Ms. DeYoung will be responsible for the company's corporate development and business development efforts, including planning and execution of strategic growth initiatives and external partnerships. Ms. DeYoung served as vice president of Business Development at Reata Pharmaceuticals, Inc. since 2008.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|